Welcome to our dedicated page for Kneat Com news (Ticker: KSIOF), a resource for investors and traders seeking the latest updates and insights on Kneat Com stock.
Kneat Com (OTCQX: KSIOF) provides mission-critical digital validation solutions for pharmaceutical, biotechnology, and medical device industries through its Kneat Gx platform. This page aggregates official press releases, regulatory updates, and strategic developments from the company, serving as a centralized hub for tracking its innovation in compliance automation.
Investors and industry professionals will find timely updates on product enhancements, partnership announcements, and operational milestones. Content spans earnings reports, technology certifications, and client success stories relevant to highly regulated sectors. All materials are sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
The curated collection enables users to monitor Kneat Com's progress in reducing validation cycle times, expanding global operations, and maintaining ISO/21 CFR compliance. Regular updates provide insights into how the company addresses evolving regulatory requirements across 60+ countries through its SaaS platform.
Bookmark this page for streamlined access to Kneat Com's latest announcements, or check back regularly to stay informed about developments impacting digital validation practices in life sciences and adjacent industries.
Kneat (KSIOF) has secured a Services Agreement with a major European-based multinational generic pharmaceuticals manufacturer to digitalize its drawing management process. The unnamed client, with over 20,000 employees and operations in more than 100 countries, will initially implement Kneat's platform at its largest European manufacturing facility.
The drawing management system will support engineering and validation processes by digitalizing technical drawings, eliminating paper-based errors, maintaining revision traceability, and controlling access. The client has the potential to expand Kneat's usage to streamline all validation workflows across their operations.
Kneat reports strong performance metrics, including a 151% net revenue retention rate as of December 31, 2024, and a 97% customer satisfaction rate rating their support as 'very good' or 'excellent'. The company serves the majority of the top 20 largest life sciences companies globally.
Kneat (KSIOF) reported strong financial results for Q4 and full year 2024, with significant growth across key metrics. Total revenue reached $13.7 million in Q4 2024, up 40% year-over-year, while SaaS revenue grew 41% to $12.5 million.
The company achieved notable improvements in profitability, with Q4 2024 gross profit increasing 48% to $10.4 million and gross margin reaching 75%. Annual Recurring Revenue (ARR) grew 60% to $59.7 million, and the company maintained a strong Net Revenue Retention Rate of 151%.
Throughout 2024, Kneat added five large strategic customers and strengthened its partner program with additions like Körber and ALTEN Group. The company completed two equity financings, raising aggregate gross proceeds of $55.6 million. In early 2025, Kneat announced new partnerships, including with Capgemini, and secured additional customer wins in the specialty therapeutics and consumer products sectors.
Kneat (TSX: KSI) (OTC: KSIOF), a company specializing in digitizing and automating validation and quality processes, has announced it will release its Q4 and full-year 2024 financial results on February 26, 2025, after TSX market close.
The company will host a conference call and Q&A session for sell-side analysts via webcast on February 27, 2025, at 09:00 ET (14:00 GMT). CEO Eddie Ryan and CFO Hugh Kavanagh will lead the presentation. The financial results will be accessible through the Financial Information section of Kneat's Investors page on their website.
Kneat (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major multinational consumer food and drink producer to digitize its validation processes. The European-headquartered company will initially implement Kneat's solutions for Equipment and Computer System Validation within its health sciences division, which employs over 5,000 people.
The agreement allows for potential expansion of Kneat's services across all affiliate companies and business divisions. This partnership demonstrates Kneat's expanding reach beyond traditional life sciences into consumer products, particularly for companies requiring validation regulatory compliance. The digitization initiative aims to help companies mitigate risk and protect their established brands.
Kneat.com (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major global therapeutics company to digitize its validation processes. The unnamed European company employs over 20,000 people across 100+ countries and operates more than ten manufacturing sites globally.
The client company provides supplies for Life Sciences organizations, focusing on research, clinical trials, manufacturing, diagnosis, and treatment. They will initially implement Kneat Gx for commissioning, qualification, and validation of manufacturing equipment and facilities. The partnership represents continued momentum for Kneat in attracting global Life Sciences leaders to its platform.
Kneat (TSX: KSI, OTCQC: KSIOF) has secured a three-year Master Services Agreement with a global medical device manufacturer to digitize their computer system validation (CSV) processes. The client, which operates in over 100 countries with manufacturing facilities in the United States, Latin America, and Europe, is part of a larger life sciences organization employing more than 15,000 people worldwide.
The agreement aims to transform the client's manual hybrid paper process into a streamlined digital solution, enhancing collaboration, visibility, speed, and harmonization for validating multiple IT systems. Kneat Gx was selected for its demonstrated ability to reduce validation costs while maintaining high compliance standards, with potential for expansion to additional validation use cases within the organization.
Kneat has signed a three-year Master Services Agreement with ALTEN SA, a global Engineering and IT Services company. ALTEN will use Kneat Gx to digitize validation processes for itself and its Life Sciences customers. With nearly 60,000 employees across 30+ countries, ALTEN serves pharmaceutical, biotechnology, medical device, and related industries. The implementation will begin with Commissioning and Qualification processes, aiming to improve efficiency and data integrity in validation workflows.
Kneat reported strong Q3 2024 financial results with total revenue reaching $12.8 million, up 52% year-over-year. The company achieved significant growth in key metrics, including a 78% increase in gross profit to $9.8 million and improved gross margin of 77%. SaaS revenue grew 48% to $11.5 million, while Annual Recurring Revenue (ARR) increased 59% to $49.9 million. The company reported positive net income of $1.2 million compared to a loss of $3.6 million in Q3 2023. Additionally, Kneat completed a bought deal offering raising $35.6 million and secured new strategic customers in the pharmaceutical and medical devices sectors.
A global medical devices manufacturer has signed a three-year Master Services Agreement with Kneat to digitize its validation processes. The client, headquartered in Germany, employs over 11,000 people and operates 30+ production sites across 15 countries in Europe, Asia and the Americas. The company provides solutions to pharma, biotech and cosmetic industries, including pharmaceutical packaging, drug delivery systems, diagnostic devices, and digital healthcare solutions. They plan to implement the Kneat Gx platform for Commissioning, Qualification and Validation (CQV) processes.
